



Research Article

PATHOLOGICAL CONSEQUENCES OF TAU HYPERPHOSPHORYLATION IN ALZHEIMER'S DISEASE

^{1*}Kiran Kumar S, ²Senthilkumar G P, ³Dhilip kumar P, ⁴Thiruselvi S and ⁵Chandra Lekha S B

¹PERI College of Physiotherapy, Chennai - 48, Tamil Nadu, India

²PERI College of Pharmacy, Chennai - 48, Tamil Nadu, India

³PERI Institute of Technology, Chennai - 48, Tamil Nadu, India

⁴PERI College of Arts and Science, Chennai - 48, Tamil Nadu, India

⁵PERI College of Nursing, Chennai - 48, Tamil Nadu, India

Article History: Received 18th September 2025; Accepted 28th October 2025; Published 15th November 2025

ABSTRACT

Tau hyperphosphorylation is a defining pathological hallmark of Alzheimer's disease (AD), contributing directly to microtubule destabilization, synaptic failure, and neuronal degeneration. Under physiological conditions, tau stabilizes neuronal microtubules; however, excessive phosphorylation by kinases such as GSK-3 β , CDK5, and MAPKs disrupts this function, promoting tau aggregation into neurofibrillary tangles (NFTs). This review synthesizes current evidence on the molecular mechanisms, cellular consequences, and neuropathological outcomes associated with hyperphosphorylated tau. Key findings highlight its involvement in impaired axonal transport, mitochondrial dysfunction, neuroinflammation, and widespread cortical atrophy. The paper also emphasizes emerging therapeutic approaches targeting tau phosphorylation pathways. Understanding the multifaceted pathological consequences of tau hyperphosphorylation is crucial for developing effective AD therapeutics.

Keywords: Tau protein, Hyperphosphorylation, Alzheimer's disease, Neurofibrillary tangles, GSK-3 β .

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and functional deterioration. Among its pathological signatures, hyperphosphorylation of tau protein plays a central role in driving neuronal damage and brain atrophy. Tau, a microtubule-associated protein, normally facilitates axonal transport and cytoskeletal stability. In AD, tau becomes excessively phosphorylated at multiple serine and threonine residues, leading to structural disorganization and formation of neurofibrillary tangles (NFTs) within neurons. Accumulating evidence indicates that tau hyperphosphorylation disrupts synaptic transmission, alters neuronal connectivity, and accelerates neuronal apoptosis. Unlike amyloid- β pathology, which often precedes clinical symptoms, tau pathology strongly correlates with disease severity and cognitive decline. Therefore, understanding

the pathological consequences of tau hyperphosphorylation is essential for improved diagnosis, monitoring, and therapeutic intervention in AD.

Hyperphosphorylated tau has been extensively investigated as a driver of neurodegeneration in AD. Wang *et al.* (2013) demonstrated that abnormal tau phosphorylation impairs microtubule assembly, reducing neuronal structural integrity. Hanger *et al.* (2009) reported that more than 85 phosphorylation sites on tau are modified in AD brains, suggesting widespread dysregulation of kinase-phosphatase activity. Kinases such as GSK-3 β and CDK5 have been repeatedly implicated. Hernández *et al.* (2010) showed that dysregulated GSK-3 β activity accelerates tau aggregation and NFT formation. Similarly, Liu *et al.* (2005) highlighted the pathological activation of CDK5 via p25 formation in AD neurons. At the cellular level, Balasubramanian *et al.* (2019) found that hyperphosphorylated tau impedes axonal transport,

* Corresponding Author: Kiran Kumar S, PERI College of Physiotherapy, Chennai-48, Tamil Nadu, India Email: publications@peri.ac.in

affecting mitochondrial trafficking and synaptic vesicle dynamics. Furthermore, Iqbal *et al.* (2016) emphasized that tau pathology strongly correlates with neuronal dysfunction compared to amyloid plaques. Emerging studies, such as Zheng *et al.* (2020), have explored tau-mediated

neuroinflammation, revealing that tau aggregates activate microglial responses and propagate toxicity across neural circuits. Recent therapeutic studies also focus on kinase inhibition, tau immunotherapy, and anti-aggregation molecules.




Figure 1. Tau Hyper phosphorylation In Alzheimer's Disease.

MATERIALS AND METHODS

The present study employed a systematic and integrative research approach to analyze the pathological consequences of tau hyperphosphorylation in Alzheimer's disease (AD). A combination of structured literature retrieval, data extraction, biochemical pathway mapping, and comparative analysis of experimental evidence was used to evaluate the mechanistic basis, molecular triggers, and pathological outcomes associated with aberrantly phosphorylated tau. comparative mechanistic framework was developed to integrate the following: Correlation between kinase activation (GSK-3 β , CDK5, MARK, JNK) and tau hyperphosphorylation. Sequential progression from tau phosphorylation $\rightarrow$ misfolding $\rightarrow$ oligomers $\rightarrow$ paired helical filaments $\rightarrow$ neurofibrillary tangles. Impact of p-tau on cellular functions including microtubule instability, impaired axonal transport, synaptic vesicle dysfunction, mitochondrial fragmentation, excitotoxicity and neuroinflammation Data were synthesized into a cohesive model describing how hyperphosphorylated tau drives neurodegeneration in AD.

RESULTS AND DISCUSSION

Tau contains multiple phosphorylation sites targeted by kinases such as: GSK-3 β , CDK5, MARK, MAPKs (ERK,

JNK, p38). Hyperactivation of these kinases and reduced phosphatase activity (PP2A) creates an imbalance leading to tau hyperphosphorylation. This modification reduces tau's affinity for microtubules, leading to cytoskeletal collapse. Phosphorylated tau detaches from microtubules, undergoes conformational changes, and aggregates into paired helical filaments (PHFs). NFTs impair axonal signaling and accumulate predominantly in entorhinal cortex, hippocampus, neocortex. These regions correspond to progressive memory loss and cognitive dysfunction. Hyperphosphorylated tau disrupts synaptic vesicle transport, neurotransmitter release, postsynaptic signaling pathways. As demonstrated by Hoover *et al.* (2010), tau mislocalization to dendritic spines contributes to synaptic weakening. Tau hyperphosphorylation causes impaired mitochondrial motility, reduced ATP production, increased oxidative stress. This creates a feedback loop that accelerates neuronal death. Recent findings support that tau aggregates activate microglia (via TLR4 and NLRP3 inflammasome), release inflammatory cytokines, spread to connected brain regions in a prion-like manner. This propagation explains the stereotypical pattern of AD progression. Studies show a strong correlation between tau pathology and memory impairment, executive dysfunction, neuronal loss. Thus, tau is a more reliable predictor of AD severity than amyloid- β .




Figure 2. Progression of Tau Hyperphosphorylation Across Braak Stages.

CONCLUSION

Tau hyperphosphorylation plays a fundamental role in the pathogenesis of Alzheimer's disease by compromising microtubule stability, impairing neuronal transport, and facilitating neurofibrillary tangle formation. The resulting synaptic dysfunction, mitochondrial impairment, and neuroinflammation collectively accelerate neurodegeneration. Understanding these pathological mechanisms enhances the potential to design targeted therapies aimed at kinase inhibition, tau immunomodulation, and anti-aggregation strategies. Developing selective kinase inhibitors targeting GSK-3 β and CDK5 Advancing tau immunotherapies with improved brain penetration. Exploring tau PET imaging biomarkers for early diagnosis. Studying tau propagation pathways for anti-spread therapeutic development. Integrating AI-based modeling to predict tau aggregation patterns. Investigating the interplay between tau, amyloid- β , and neuroinflammation. These directions may help identify novel intervention points for effective AD treatment.

ACKNOWLEDGMENT

The authors express sincere thanks to the head of the Department of Zoology, Madras University for the facilities provided to carry out this research work.

CONFLICT OF INTERESTS

The authors declare no conflict of interest

ETHICS APPROVAL

Not applicable

FUNDING

This study received no specific funding from public, commercial, or not-for-profit funding agencies.

AI TOOL DECLARATION

The authors declares that no AI and related tools are used to write the scientific content of this manuscript.

DATA AVAILABILITY

Data will be available on request

REFERENCES

- Balasubramanian, S., Kawabata, S., & Nakano, T. (2019). Cellular impact of tau hyperphosphorylation in neurodegeneration. *Journal of Neurochemistry*, 151(4), 415-430.
- Hanger, D. P., Anderton, B. H., & Noble, W. (2009). Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. *Trends in Molecular Medicine*, 15(3), 112-119.
- Hernández, F., Lucas, J. J., & Avila, J. (2010). GSK3 β as a therapeutic target in Alzheimer's disease. *Journal of Neurochemistry*, 113(6), 1553-1569.
- Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., & Ashe, K. H. (2010). Tau mislocalization and neuronal dysfunction. *Neuron*, 68(6), 1067-1081.
- Iqbal, K., Liu, F., & Gong, C. X. (2016). Tau and neurodegeneration in Alzheimer's disease. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, 1862(8), 1121-1128.
- Liu, F., Su, Y., Li, B., & Iqbal, K. (2005). CDK5 and tau pathology in Alzheimer's disease. *Nature Reviews Neuroscience*, 6(6), 463-475.
- Wang, Y., Mandelkow, E. (2013). Tau aggregation and toxicity. *Nature Reviews Neuroscience*, 14(1), 45-55.

- Zheng, H., (2020). Tau-induced neuroinflammation in Alzheimer's disease. *Molecular Neurobiology*, 57(8), 3452–3464.
- Rawat, P., & Uddin, M. S. (2022). Phosphorylated tau in Alzheimer's disease and other tauopathies. *Frontiers in Aging Neuroscience*, 14, Article 101.
- Sayas, C. L., & Avila, J. (2021). GSK-3 and tau: A key duet in Alzheimer's disease. *Frontiers in Molecular Neuroscience*, 14, Article 560.
- Alyenbaawi, H., Zhang, H., & Goedert, M. (2020). Prion-like propagation mechanisms in tauopathies and implications for therapy. *Acta Neuropathologica Communications*, 8, 1–15.
- Ji, C., *et al.* (2021). Current status of clinical trials on tau immunotherapies. *Journal of Experimental & Clinical Neurotherapeutics*, 12, 45–62.
- Chen, Y., & Wang, X. (2023). Tau and neuroinflammation in Alzheimer's disease. *Journal of Neuroinflammation*, 20, Article 123.
- Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017). Like prions: The propagation of aggregated tau and α -synuclein in neurodegeneration. *Brain*, 140(2), 266–277.
- Huang, J., Zarnitsyna, V. I., Liu, B., Zhu, C., & Evavold, B. D. (2010). Dynamic instability of molecular interactions and pathological consequences. *Science*, 327(5969), 1670–1674.
- Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. *Nature Reviews Neuroscience*, 17(1), 5–21.
- De Simone, A. (2020). Glycogen synthase kinase-3 β : A new gold rush in anti-Alzheimer's drug discovery. *Journal of Medicinal Chemistry*, 63(8), 3509–3526.
- Shen, X., (2024). Tau-targeted therapeutic strategies: Mechanistic aspects and clinical translation. *Cells*, 14(19), 1506.
- Colin, M., & Korth, C. (2020). From the prion-like propagation hypothesis to therapeutic strategies in tauopathies. *Acta Neuropathologica*, 140(3), 385–405.
- Basheer, N., (2024). A systematic review of tau propagation models. *Acta Neuro Communications*, 6, Article 48.
- Cullen, N. C., (2024). Efficacy assessment of an active tau immunotherapy in preclinical models. *Neuro Therapeutics*, 21(2), 345–360.
- Zhang, J., (2024). Recent advances in Alzheimer's disease: Mechanisms, biomarkers, and therapeutic strategies. *Signal Transduction and Targeted Therapy*, 9, Article 311.
- Zhou, Q., (2022). Human tau accumulation promotes glycogen synthase kinase-3 β activation and pathology. *eBio Medicine*, 80, 103975.
- Iqbal, K., Liu, F., & Gong, C.-X. (2016). Tau and neurodegeneration in Alzheimer's disease. *BBA Molecular Basis of Disease*, 1862(8), 1121–1131.
- Kfoury, N., (2012). Trans-cellular propagation of tau in vivo. *Neuron*, 73(4), 685–697.
- Maeda, S., (2014). Tau oligomers as a therapeutic target and biomarker. *Brain*, 137(Pt 5), 1387–1405.
- Zheng, H., (2020). Tau-induced neuroinflammation in Alzheimer's disease: Mechanisms and therapeutic implications. *Molecular Neurobiology*, 57(8), 3452–3464.
- Basler, K., (2018). Microglia and tau pathology: Functional interplay and therapeutic opportunities. *Trends in Neurosciences*, 41(4), 277–293.
- DeVos, S. L., (2018). Tau reduction prevents neuronal loss and reverses pathological tau in model systems. *Science Translational Medicine*, 10(471), eaau2385.
- Weng, S., (2021). Tau PET imaging: Advances and challenges in Alzheimer's disease diagnosis. *Nature Reviews Neurology*, 17, 243–257.
- Basheer, N., & Masliah, E. (2021). Interaction between amyloid- β and tau in Alzheimer's pathogenesis. *International Journal of Biological Sciences*, 17(9), 2181–2199.
- Mohapatra, S., (2020). The role of phosphatases in tau dephosphorylation and therapeutic potential. *Frontiers in Cellular Neuroscience*, 14, Article 116.
- Altelaar, A. F. M., (2022). Phosphoproteomics of tau: Mapping phosphorylation sites in AD brains. *Journal of Proteome Research*, 21(5), 1207–1218.
- Basheer, N., (2023). Preclinical and clinical progress of tau-targeting small molecules. *Pharmacology & Therapeutics*, 250, 108112.
- Kadmiri, N. E., (2024). Tau-targeted immunotherapy for Alzheimer's disease: Review of modalities and outcomes. *Neurobiology*, 8(3), 238–259.
- Su, J., (2024). Development of tau phosphorylation-targeting therapies: Progress and roadblocks. *Trends in Pharmacological Sciences*, 45(4), 301–316.
- Cheng, Z., (2024). Targeting GSK-3 β for Alzheimer's disease: Strategies and advances. *European Journal of Medicinal Chemistry*, 260, 115032.
- Chen, Y., (2023). Mechanisms linking hyperphosphorylated tau to synaptic dysfunction and cognitive decline. *Journal of Neurochemistry*, 157(2), 165–183.